|
|
||||||||
Institut National de la Santé et de la Recherche Médicale Unité 28, Institut Fédératif de Recherche 30, Hôpital Purpan, Toulouse, France
The mechanisms that influence the polarization of CD4 T cells
specific for allogeneic MHC class II molecules in vivo are still poorly
understood. We have examined the pathway of alloreactive CD4 T cell
differentiation in a situation in which only CD4 T cells could be
activated in vivo. In this report we show that priming of adult mice
with allogeneic APC, in the absence of MHC class I-T cell interactions,
induces a strong expansion of type 2 cytokine-producing allohelper T
cells. These alloantigen-specific CD4 T cells directly recognize native
allogeneic MHC class II molecules on APC and secrete, in addition to
the prototypic Th2 cytokines IL-4, IL-5, and IL-10, large amounts of
TGF-ß. The default Th2-phenotype acquisition is not genetically
controlled and occurred both in BALB/c and C57BL/6 mice. CD8 T cells
are the principal cell type that controls CD4 T cell differentiation in
vivo. Furthermore, we demonstrate that strong Th2 priming can be
induced not only with allogeneic splenocytes but also with a low number
of bone marrow-derived dendritic cells. Finally, using a passive
transfer system, we provide direct evidence that CD8 T cell expansion
in situ promotes alloreactive Th1 cell development principally by
preventing their default development to the Th2 pathway in a mechanism
that is largely IFN-
independent. Therefore, this work demonstrates
that type 2 cytokine production represents a dominant pathway of
alloreactive CD4 T cell differentiation in adult mice, a phenomenon
that was initially thought to occur only during the neonatal
period.
This article has been cited by other articles:
![]() |
S. Laffont, C. Seillet, J. Ortaldo, J. D. Coudert, and J.-C. Guery Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells Blood, August 1, 2008; 112(3): 661 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. LaRosa, A. H. Rahman, and L. A. Turka The Innate Immune System in Allograft Rejection and Tolerance J. Immunol., June 15, 2007; 178(12): 7503 - 7509. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Laffont, J. D. Coudert, L. Garidou, L. Delpy, A. Wiedemann, C. Demur, C. Coureau, and J.-C. Guery CD8+ T-cell-mediated killing of donor dendritic cells prevents alloreactive T helper type-2 responses in vivo Blood, October 1, 2006; 108(7): 2257 - 2264. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Delpy, V. Douin-Echinard, L. Garidou, C. Bruand, A. Saoudi, and J.-C. Guery Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses J. Immunol., October 15, 2005; 175(8): 5050 - 5057. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Garidou, S. Laffont, V. Douin-Echinard, C. Coureau, A. Krust, P. Chambon, and J.-C. Guery Estrogen Receptor {alpha} Signaling in Inflammatory Leukocytes Is Dispensable for 17{beta}-Estradiol-Mediated Inhibition of Experimental Autoimmune Encephalomyelitis J. Immunol., August 15, 2004; 173(4): 2435 - 2442. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Adams, N. Nagy, F. Paulart, M.-L. Vanderhaeghen, M. Goldman, and V. Flamand CD8+ T Lymphocytes Regulating Th2 Pathology Escape Neonatal Tolerization J. Immunol., November 15, 2003; 171(10): 5071 - 5076. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Buonocore, F. Paulart, A. Le Moine, M. Braun, I. Salmon, S. Van Meirvenne, K. Thielemans, M. Goldman, and V. Flamand Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo Blood, February 15, 2003; 101(4): 1469 - 1476. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Coudert, C. Coureau, and J.-C. Guery Preventing NK Cell Activation by Donor Dendritic Cells Enhances Allospecific CD4 T Cell Priming and Promotes Th Type 2 Responses to Transplantation Antigens J. Immunol., September 15, 2002; 169(6): 2979 - 2987. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |